Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Biologists ID New Cancer Weakness

Published: Monday, November 18, 2013
Last Updated: Monday, November 18, 2013
Bookmark and Share
Drugs that block new target gene could make many tumors more vulnerable to chemotherapy.

About half of all cancer patients have a mutation in a gene called p53, which allows tumors to survive and continue growing even after chemotherapy severely damages their DNA.

A new study from MIT biologists has found that tumor cells with mutated p53 can be made much more vulnerable to chemotherapy by blocking another gene called MK2. In a study of mice, tumors lacking both p53 and MK2 shrank dramatically when treated with the drug cisplatin, while tumors with functional MK2 kept growing after treatment.

The findings suggest that giving cancer patients a combination of a DNA-damaging drug and an MK2 inhibitor could be very effective, says Michael Yaffe, the David H. Koch Professor in Science and senior author of a paper describing the research in the Nov. 14 issue of the journal Cell Reports.

Several drugs that inhibit MK2 are now in clinical trials to treat inflammatory diseases such as arthritis and colitis, but the drugs have never been tested as possible cancer treatments.

“What our study really says is that these drugs could have an entirely new second life, in combination with chemotherapy,” says Yaffe, who is a member of MIT’s Koch Institute for Integrative Cancer Research. “We’re very much hoping it will go into clinical trials” for cancer.

Sandra Morandell, a postdoc at the Koch Institute, is the paper’s lead author.

To kill a tumor

P53 is a tumor-suppressor protein that controls cell division. Before cell division begins, p53 checks the cell’s DNA and initiates repair, if necessary. If DNA damage is too extensive, p53 forces the cell to undergo programmed cell death, or apoptosis. Tumors that lack p53 can avoid this fate.

“Usually p53 is the main driver of cell death, and if cells lose this pathway they become very resistant to different treatments that cause cell death,” Morandell says.

Several years ago, researchers in Yaffe’s lab discovered that in cancer cells with mutated p53, the MK2 gene helps counteract the effects of chemotherapy. When cancer cells suffer DNA damage, MK2 puts the brakes on the cell division cycle, giving cells time to repair the damage before dividing.

“Our data suggested if you block the MK2 pathway, tumor cells wouldn’t recognize that they had DNA damage and they would keep trying to divide despite having DNA damage, and they would end up committing suicide,” Yaffe says.

In the new study, the researchers wanted to see if this would hold true in tumors in living animals, as well as cells grown in a lab dish. To do that, they used a strain of mice that are genetically programmed to develop non-small-cell lung tumors. The researchers further engineered the mice so they could reversibly turn the MK2 gene on or off, allowing them to study tumors with and without MK2 in the same animal.

This new approach allows them, for the first time, to compare different types of tumors in the same mice, where all genetic factors are identical except for MK2 expression.

"This is a very elegant and potentially useful approach for others to use," says Titia de Lange, a professor of cell biology and genetics at Rockefeller University, who was not part of the research team.

Using these mice, the researchers found that before treatment, tumors lacking both MK2 and p53 grow faster than tumors that have MK2. This suggests that treating tumors with an MK2 inhibitor alone would actually do more harm than good, possibly increasing the tumor’s growth rate by taking the brake off the cell cycle.

However, when these tumors are treated with cisplatin, the tumors lacking MK2 shrink dramatically, while those with MK2 continue growing.

‘A nonobvious combination’

The potential combination of cisplatin and MK2 inhibitors is unlike other chemotherapy combinations that have been approved by the Food and Drug Administration, which consist of pairs of drugs that each show benefit on their own. “What we found is a combination that you would never have arrived at otherwise,” Yaffe says. “It’s a nonobvious combination.”

While this study focused on non-small-cell lung tumors, the researchers have gotten similar results in cancer cells grown in the lab from bone, cervical, and ovarian tumors. They are now studying mouse models of colon and ovarian cancer.

The research was funded by the Austrian Science Fund, the National Institutes of Health, Janssen Pharmaceuticals Inc., the Koch Institute, MIT’s Center for Environmental Health Sciences, the Volkswagenstiftung, the Deutsche Forschungsgemeinschaft, the German Ministry for Science and Technology, the Deutsche Jose Carreras Leukämie Stiftung, and the Anna Fuller Fund.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Capsule Achieves Long-Term Drug Delivery
Novel drug delivery method could aid in elimination of malaria and treatment of many other diseases.
Monday, November 21, 2016
Predicting Cancer Cells’ Response to Chemotherapy
Researcher develop method for testing cell ability to perform different types of DNA repair, which can reveal tumors’ sensitivity to drugs.
Wednesday, November 02, 2016
Fighting Cancer with the Power of Immunity
Researchers at MIT have used a combination of four different therapies to activate both of the immune system’s two branches, producing a coordinated attack that led to the complete disappearance of large, aggressive tumors in mice.
Friday, October 28, 2016
Fighting Cancer with Immune Response
New treatment elicits two-pronged immune response that destroys tumors in mice.
Tuesday, October 25, 2016
Nanosensors Could Determine Tumours’ Ability to Remodel Tissue
Researchers design nanosensors that can profile tumours, focusing on protease levels.
Thursday, September 29, 2016
High-Capacity Nanoparticles
New type of nanoparticle can now have three or more drugs packaged within it, allowing for customised cancer therapy.
Thursday, September 15, 2016
Delivering Beneficial Bacteria
Method that transports microbes through the stomach to the intestine may benefit human health.
Thursday, September 15, 2016
Linking RNA Structure and Function
Biologists have deciphered a lncRNA structure and used the information to investigate its cellular protein interactions.
Friday, September 09, 2016
Triple-Action Therapy Patch Shows Promise
Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results in mice.
Wednesday, July 27, 2016
New Device can Study Electric Field Cancer Therapy
Microfluidic device allows study of electric field cancer therapy through low-intensity fields, preventing malignant cells spreading.
Friday, July 08, 2016
Long-Term Drug Release
New tablet attaches to the lining of the GI tract, resists being pulled away.
Thursday, April 07, 2016
Cancer Cells Remodel Environments Before Spreading
Researchers at MIT have found that the cancer cells remodel their environment to make it easier to reach nearby blood vessels.
Wednesday, March 16, 2016
Paving the Way for Metastasis
Cancer cells remodel their environment to make it easier to reach nearby blood vessels.
Tuesday, March 15, 2016
Curing Disease by Repairing Faulty Genes
New delivery method boosts efficiency of CRISPR genome-editing system.
Wednesday, February 03, 2016
No More Insulin Injections?
Encapsulated pancreatic cells offer possible new diabetes treatment.
Tuesday, January 26, 2016
Scientific News
New Mechanism to Control Human Viral Infections Discovered
Researchers discover long sought after mechanism in human cells that could help treat diseases caused by viruses.
Study Reveals New Role for Hippo Pathway in Suppressing Cancer Immunity
Hippo pathway signaling regulates organ size by moderating cell growth, apoptosis and stem cell renewal, but dysregulation contributes to cancer development.
RNAi Activated in Response to Influenza
Discovery could lead to better ways of combating serious infections, including Ebola and Zika.
Gene Therapy Maintains Clotting Factor for Hemophilia Patients
Following a single gene therapy dose, the highest levels of an essential blood clotting factor IX were observed in hemophilia B patients.
Transporting Microscopic Cargo Between Human Cells
Scientists have developed a virus-inspired delivery system for material transport between cells.
Improving Drug Production with Computer Model
A model has been developed that can be used to improve and accelerate the production of biotherapeutics, cancer drugs, and vaccines.
Turning Off Asthma Attacks
Researchers discover a critical cellular “off” switch for the inflammatory immune response that causes asthma attacks.
New Strategy May Drop Cancer’s Guard
Scientists eye ways to deconstruct tumors’ protective wall with current diabetes drug.
Scientists Identify Unique Genomic Features in Testicular Cancer
The findings may shed light on factors in other cancers that influence their sensitivity to chemotherapy.
Smart Patch Releases Blood Thinners When Needed
Researchers have developed a smart patch that activelly monitors a patient's blood and releases blood thinning drugs when necessary.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!